statistics
 
Home   Contact Us   Sitemap



 Overview  Vision - Mission  Milestones  Accolades  Board of Directors  Committee of Directors
 History  History  Social Responsibility  
 
 
Milestones :
 
 
 2017 - Indoco receives UKMHRA approval for solid dosages Plant I in Goa
  - Indoco receives the IDMA Best Patent Award for four API Process Patents
  - Indoco receives patent grant for Linezolid & Brinzolamide (FDFs) from United States Patent and Trademark Office (USPTO).
   
 2016 - Indoco Honoured with the IDMA Best Patent Award for Three International Patents
  - Indoco achieves a milestone of Rs.1000 Crs.
  - Indoco acquires Oral Solid Dosage manufacturing facility in Baddi from Micro Labs Ltd., Bangalore
  - Indoco's Allopurinol ANDA gets USFDA approval
  - Indoco climbs 187 ranks up - Fortune India
  - Indoco receives USFDA approval for solid dosages Plant I in Goa
  - Indoco honoured with the 'Best Patent Award' by PHARMEXCIL in the Bulk Drugs / API category
   
 2015 - Indoco wins IDMA Patent Appreciation Award for Betaxolol
   
 2014 - US-FDA approves Sterile (Plant II) and Solid Dosages (Plant III) facilities in Goa
  - IDMA Best Patent Award for Tazarotene & Adapalene
   
 2012 - Indoco announced the signing of an agreement with DSM, a 9 billion Company, for commercial cooperation for Active Pharmaceutical Ingredients (APIs). Indoco and DSM have formed a strategic alliance, wherein DSM shall be marketing and selling the APIs manufactured by INDOCO.
  - Innovation in Quality Award at CPhI Pharma Awards
   
 2011 - Indoco received the Silver Quality Excellence Award for Sterile Manufacturing Facility in Goa and Solid Dosages Facility in Baddi (Himachal\Pradesh) at IDMA's Golden Jubilee celebrations.
   
 2010 - Indoco Remedies teams up with ASPEN, South Africa by licensing out intellectual property (dossiers) for marketing its products in emerging markets covering 30 countries, including SA, Brazil, Mexico, Venezuela, Russia & Australia.
  - Indoco Remedies licenses out technology to Watson Pharmaceuticals Inc. USA. Under the terms of profit sharing agreement, Indoco will develop, manufacture and supply a basket of sterile products to Watson for the US market.
   
 2009 - UK-MHRA approval for the Solid Oral Dosage forms at Baddi Plant.
  - Export sales exceeded Rs. 1 Billion in the FY 08-09.
  - Successfully faced Slovenia audit for the Sterile Facility at Goa Plant II for the Injections Area.
   
 2008 - IDMA Quality Excellence Awards 2008 - The Sterile Facility at Goa Plant II received the Gold Award and the Solid Dosage Forms and Externals Facility at Goa Plant I received the Silver Award.
  - TGA (Australia) approval for the Solid Dosage, Liquid Orals and Creams & Ointments Dosage forms at GOA Plant I.
  - First shipment of Diclofenac Ophthalmic solution shipped to USA against an approved ANDA.
  - Successfully faced Slovenia audit for the Solid Oral Dosage forms at Baddi Plant.
  - MCC (South Africa) approval for the Solid Dosage facility at GOA Plant I and for the Sterile facility at Goa Plant II.
   
 2007 - ANVISA (Brazil) approval for the Solid Dosage facility at GOA Plant I.
  - Commencement of exports to the US markets.
  - Launch of Warren-Excel and Spera - two specialty marketing divisions.
   
 2006 - US-FDA approval for Ophthalmic facility, Plant-II in GOA.
  - Contract signed for supply of 18 generic products to German Market.
  - 2 ANDAs filed with USFDA.
  - Commencement of liquid manufacturing facility at Baddi, Himachal Pradesh.
  - New R&D Centre at Rabale, near Mumbai becomes functional.
  - Solid Dosage facility at Goa Plant I re-inspected & approved by UK-MHRA.
  - UK-MHRA approval for Creams & Ointments facility.
  - Darmstadt-Germany approves our Goa facility for Solid Dosage manufacturing.
  - Acquisition of LaNOVA Chem Pvt. Ltd. with its brand new API manufacturing facility of international standards.
  - Launch of Surge - a specialty marketing division.
   
 2005 - First ANDA filed on the basis of Exhibit batches manufactured in our sterile facility in Goa.
  - Development Contracts for injectable products signed with a US Company.
  - Tablet capacity doubled by commissioning an extended facility in the existing UK-MHRA approved plant.
  - Shares of the Company listed on BSE and NSE.
   
 2004 - First Contract for Development services with US Company.
  - Karvol brand acquisition from Solvay Pharmaceuticals Pvt. Ltd.
  - Four Patent applications filed.
  - Company jumps five ranks in two yrs in the ORG-IMS Retail Audit.
   
 2003 - UK-MHRA approval for the Solid Dosage facility at Plant I.
  - Exports to regulated markets commence.
  - First contract for Dossier Development with European company.
  - Domestic Marketing makes a foray into the lifestyle segment.
   
 2002 - State-of-the-art sterile facility, Plant II commissioned at Verna Goa.
   
 1999 - New Corporate Office at Indoco House.
  - Acquisition of Warren, Company makes presence in Ophthalmic & Dental Segments.
   
 1997 - Commencement of production in Goa Plant I.
   
 1993 - R&D recognized by DSIR.